AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8427323 — intervention group
Group type: COMPARATOR
Intervention: Historical Comparison Group (C)
Number of subjects: 814
Study 8427323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis
Number of subjects: 814
Study 2884895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 microgram/kg
Number of subjects: 0
Study 2884895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1 microgram/kg
Number of subjects: 0
Study 2884895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sufentanil)
Number of subjects: 0
Study 29654645 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (100 mg testosterone enanthate weekly for 7 weeks)
Number of subjects: 28
Study 29654645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29654645 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 28
Study 26657900 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-Dose Group (SDG) - low-volume 2-L polyethylene glycol (PEG)-ascorbate solution in a 'split-dose' regimen
Number of subjects: 690
Study 26657900 — intervention group
Group type: COMPARATOR
Intervention: Day-Before Group (DBG) - traditional 'full-dose, day-before' regimen
Number of subjects: 690
Study 26657900 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-Dose Group (SDG)
Number of subjects: 690
Study 26657900 — intervention group
Group type: COMPARATOR
Intervention: Day-Before Group (DBG)
Number of subjects: 690
Study 26021558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells within 24 hours (group A, n = 27)
Number of subjects: 104
Study 26021558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells 3 to 7 days after PCI (group B, n = 26)
Number of subjects: 104
Study 26021558 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25) - saline infusion performed immediately after emergency PCI
Number of subjects: 104
Study 26021558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells 7 to 30 days after PCI (group C, n = 26)
Number of subjects: 104
Study 26021558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells within 24 hours (group A)
Number of subjects: 104
Study 26021558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells 3 to 7 days after PCI (group B)
Number of subjects: 104
Study 26021558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mononuclear cells 7 to 30 days after PCI (group C)
Number of subjects: 104
Study 23819670 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term group psychotherapy
Number of subjects: 0
Study 21421664 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-day NOMAC/E2 regimen
Number of subjects: 77
Study 21421664 — intervention group
Group type: COMPARATOR
Intervention: 21-day NOMAC/E2 regimen
Number of subjects: 77
Study 18797670 — intervention group
Group type: COMPARATOR
Intervention: CAT and placebo eyedrops (PED)
Number of subjects: 29
Study 18797670 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT, 0.015% MMC subconjunctivally, and PED
Number of subjects: 29
Study 18797670 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT and 0.02% MMC eyedrops
Number of subjects: 29
Study 14763319 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical method for evaluating labor progress
Number of subjects: 0
Study 14763319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest-posttest analysis
Number of subjects: 0
Study 11239222 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg single dose)
Number of subjects: 40
Study 11239222 — intervention group
Group type: COMPARATOR
Intervention: No amifostine
Number of subjects: 40
Study 11239222 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 40
Study 9727725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 600 mg per day
Number of subjects: 20
Study 9727725 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 1600 mg per day
Number of subjects: 20
Study 9727725 — intervention group
Group type: COMPARATOR
Intervention: Control group (unchanged medication)
Number of subjects: 20
Study 8281696 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 312
Study 8281696 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator
Number of subjects: 312
Study 8281696 — intervention group
Group type: EXPERIMENTAL
Intervention: Patency of the infarct‐related artery (TIMI 3 flow)
Number of subjects: 312
Study 8281696 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion score (amount of myocardium supplied by an occluded artery)
Number of subjects: 312
Study 8281696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction > or = 50%
Number of subjects: 312
Study 8281696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction < 50%
Number of subjects: 312
Study 8281696 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise duration 4 weeks after infarction
Number of subjects: 312
Study 2735560 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil
Number of subjects: 29
Study 2735560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 29
Study 2735560 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 29
Study 21750157 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (hGH), 20 μg/kg/day
Number of subjects: 712
Study 21750157 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 712
Study 31928085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip and soft palate closure at 3 to 4 months and hard palate closure at 12 months (arm A)
Number of subjects: 136
Study 31928085 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip and hard palate closure at 3 to 4 months and soft palate closure at 12 months (arm D)
Number of subjects: 136
Study 30975155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboriginal Identification in Hospitals Quality Improvement Program (AIHQIP)
Number of subjects: 8
Study 30975155 — intervention group
Group type: COMPARATOR
Intervention: Control (no AIHQIP implementation)
Number of subjects: 8
Study 30975155 — intervention group
Group type: EXPERIMENTAL
Intervention: AIHQIP
Number of subjects: 8
Study 29871262 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and radiotherapy
Number of subjects: 190
Study 29871262 — intervention group
Group type: COMPARATOR
Intervention: Concurrent radiotherapy and chemotherapy plus adjuvant chemotherapy
Number of subjects: 190
Study 26160958 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid
Number of subjects: 8
Study 23256145 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk intake (≥237 mL/d or 1 serving/d)
Number of subjects: 21660
Study 23256145 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk intake
Number of subjects: 21660
Study 23256145 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim/low-fat milk intake
Number of subjects: 21660
Study 23256145 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dairy products intake (>2.5 servings/d)
Number of subjects: 21660
Study 21489301 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 92
Study 21489301 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative or indeterminate
Number of subjects: 92
Study 19893969 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil‐containing mouthrinse (EO)
Number of subjects: 159
Study 19893969 — intervention group
Group type: COMPARATOR
Intervention: 0.05% CPC with alcohol (CPCa)
Number of subjects: 159
Study 19893969 — intervention group
Group type: COMPARATOR
Intervention: 0.05% CPC alcohol‐free (CPCna)
Number of subjects: 159
Study 19893969 — intervention group
Group type: COMPARATOR
Intervention: 5% hydroalcohol negative control
Number of subjects: 159
Study 16467972 — intervention group
Group type: EXPERIMENTAL
Intervention: School curriculum-based exercise intervention program (40 minutes/school day)
Number of subjects: 53
Study 16467972 — intervention group
Group type: COMPARATOR
Intervention: Control group (60 minutes physical activity/week)
Number of subjects: 53
Study 15849392 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (n=22)
Number of subjects: 96
Study 15849392 — intervention group
Group type: COMPARATOR
Intervention: No antenatal corticosteroids (n=74)
Number of subjects: 96
Study 10958572 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLRP
Number of subjects: 120
Study 10958572 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 120
Study 9311396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 169
Study 9311396 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 169
Study 8348110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000 mg once daily)
Number of subjects: 198
Study 8348110 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg once daily)
Number of subjects: 198
Study 3789368 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal morphine 10 mg tablets
Number of subjects: 50
Study 3789368 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate 13.5 mg
Number of subjects: 50
Study 29346249 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 500
Study 29346249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 500
Study 29346249 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 1% vs 2% lignocaine
Number of subjects: 500
Study 27447721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free beverage (250 mL per day) for 18 months
Number of subjects: 477
Study 24332142 — intervention group
Group type: EXPERIMENTAL
Intervention: Full prescription coverage with adherence (proportion of days covered ≥80%) to statin, β-blocker, or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
Number of subjects: 0
Study 24332142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherent patients
Number of subjects: 0
Study 24332142 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially adherent patients
Number of subjects: 0
Study 24332142 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 22418773 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg once daily (QD)
Number of subjects: 50
Study 22418773 — intervention group
Group type: COMPARATOR
Intervention: Neratinib 120 mg twice daily (BID)
Number of subjects: 50
Study 20532178 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir with tenofovir-emtricitabine
Number of subjects: 148
Study 20532178 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir with tenofovir-emtricitabine
Number of subjects: 148
Study 20532178 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI TDRs
Number of subjects: 148
Study 20532178 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI TDRs
Number of subjects: 148
Study 20532178 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple TAMs
Number of subjects: 148
Study 20532178 — intervention group
Group type: EXPERIMENTAL
Intervention: M184V/I
Number of subjects: 148
Study 20532178 — intervention group
Group type: EXPERIMENTAL
Intervention: PI TDRs
Number of subjects: 148
Study 17934715 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic ACL reconstruction with Delta plasty using hamstrings as auto-grafts
Number of subjects: 41
Study 16126738 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 97
Study 11929644 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinyl estradiol + 2 mg dienogest (30 EE/DNG)
Number of subjects: 100
Study 11929644 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol + 2 mg dienogest (20 EE/DNG)
Number of subjects: 100
Study 11929644 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg ethinyl estradiol + 2 mg estradiol valerate + 2 mg dienogest (EE/EV/DNG)
Number of subjects: 100
Study 11929644 — intervention group
Group type: COMPARATOR
Intervention: 20 microg ethinyl estradiol + 100 microg levonorgestrel (EE/LNG)
Number of subjects: 100
Study 10384247 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (12 sessions of 1/2 hr duration)
Number of subjects: 50
Study 10384247 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation (6 sessions of 1 hr each)
Number of subjects: 50
Study 10384247 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring control group (10 children)
Number of subjects: 50
Study 8588965 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 and H2-receptor-blocking agents in standard dosages preoperatively (Antihistamine group)
Number of subjects: 30
Study 8588965 — intervention group
Group type: COMPARATOR
Intervention: No histamine-receptor-blocking agents (Control group)
Number of subjects: 30
Study 2650532 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible light-cured material
Number of subjects: 52
Study 2650532 — intervention group
Group type: COMPARATOR
Intervention: Chemically cured adhesive
Number of subjects: 52
Study 2650532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of all adhesive/base combinations
Number of subjects: 52
Study 1089400 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 1089400 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 0
Study 1089400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30772189 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric hamstring training (ECC)
Number of subjects: 30
Study 30772189 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric hamstring training (CON)
Number of subjects: 30
Study 30772189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 28681626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (100, 200, 400, 600, 800 mcg)
Number of subjects: 50
Study 28681626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (400, 600, 800 mcg)
Number of subjects: 50
Study 28681626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (600, 800 mcg)
Number of subjects: 50
Study 28681626 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl citrate IV
Number of subjects: 50
Study 25123256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-set combined exercise protocol (30 min of aerobic exercise at 65-70% of reserve heart rate and 1 set of 8-12 repetitions at 80% of 10-RM in six resistance exercises)
Number of subjects: 16
Study 25123256 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-sets combined exercise protocol (same as 1-set but with 3 sets)
Number of subjects: 16
Study 25123256 — intervention group
Group type: COMPARATOR
Intervention: Control session (30 min of seated rest)
Number of subjects: 16
Study 23439692 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes prevention program (intervention group)
Number of subjects: 58
Study 23439692 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 58
Study 23439692 — intervention group
Group type: COMPARATOR
Intervention: Healthy living diabetes prevention presentations
Number of subjects: 58
Study 23439692 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly reminder calls and homework assignments
Number of subjects: 58
Study 21909495 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno IV (self-etch adhesive)
Number of subjects: 40
Study 21909495 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond (etch-and-rinse adhesive)
Number of subjects: 40
Study 21909495 — intervention group
Group type: COMPARATOR
Intervention: Adper‐Scotchbond SE (etch-and-rinse adhesive)
Number of subjects: 40
Study 21909495 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse systems
Number of subjects: 40
Study 21909495 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching systems
Number of subjects: 40
Study 19578819 — intervention group
Group type: EXPERIMENTAL
Intervention: Full apology and acceptance of responsibility
Number of subjects: 200
Study 19578819 — intervention group
Group type: COMPARATOR
Intervention: No apology and no responsibility
Number of subjects: 200
Study 19578819 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived apology and responsibility
Number of subjects: 200
Study 16510637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pneumococcal conjugate and polysaccharide vaccinations
Number of subjects: 161
Study 16510637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccinations
Number of subjects: 161
Study 16510637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional vaccination)
Number of subjects: 161
Study 12775969 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil infusion
Number of subjects: 0
Study 12775969 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 16451393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral deferiprone (L1)
Number of subjects: 36
Study 16451393 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous desferrioxamine (DF)
Number of subjects: 36
Study 10891831 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) combined with intensive diabetes management (IDM)
Number of subjects: 77
Study 10891831 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 77
Study 10891831 — intervention group
Group type: COMPARATOR
Intervention: Intensive diabetes management (IDM) alone
Number of subjects: 77
Study 8654655 — intervention group
Group type: EXPERIMENTAL
Intervention: Large loop excision of the transformation zone of the cervix
Number of subjects: 33
Study 8654655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cervical surgery)
Number of subjects: 33
Study 2068599 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV (experimental anti-HIV drug)
Number of subjects: 40
Study 2068599 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 40
Study 6340975 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol 4-hourly
Number of subjects: 12
Study 6340975 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol 2-hourly
Number of subjects: 12
Study 6340975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31939564 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 50
Study 31939564 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous parasacral stimulation
Number of subjects: 50
Study 27730298 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring using the GEx System (intervention group, IG)
Number of subjects: 118
Study 27730298 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation (control group, CG)
Number of subjects: 118
Study 27221319 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ACS) intervention
Number of subjects: 0
Study 27221319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACS intervention)
Number of subjects: 0
Study 24132855 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from specialist healthcare services during the last 6 months of life
Number of subjects: 2444
Study 24132855 — intervention group
Group type: EXPERIMENTAL
Intervention: Links with external healthcare providers (GP, palliative care nurses, physiotherapy)
Number of subjects: 2444
Study 24132855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependency of residents
Number of subjects: 2444
Study 22302355 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 424
Study 20626053 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese Magnetic Pearls
Number of subjects: 84
Study 20626053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccaria seeds
Number of subjects: 84
Study 20626053 — intervention group
Group type: COMPARATOR
Intervention: Control (tape treatment only)
Number of subjects: 84
Study 20626053 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 84
Study 17142247 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completed agenda form (SCAF)
Number of subjects: 3124
Study 17142247 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SCAF)
Number of subjects: 3124
Study 16335045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite
Number of subjects: 100
Study 16335045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Number of subjects: 100
Study 16335045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrexidin
Number of subjects: 100
Study 16335045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubulicid Plus
Number of subjects: 100
Study 16335045 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study 12517329 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of low-dose dopamine (3 microg/kg/min)
Number of subjects: 80
Study 12517329 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 5 mg/hr infusion
Number of subjects: 80
Study 12517329 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 80
Study 12517329 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dopamine
Number of subjects: 80
Study 9658737 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 32
Study 7660061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus patients with normal hearing or slight hearing loss
Number of subjects: 113
Study 7660061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus patients with moderate to pronounced sensorineural hearing loss
Number of subjects: 113
Study 7660061 — intervention group
Group type: COMPARATOR
Intervention: Controls (220 matched individuals)
Number of subjects: 113
Study 2486945 — intervention group
Group type: EXPERIMENTAL
Intervention: Flame Test
Number of subjects: 116